Literature DB >> 21663498

Role of gut microbiota in graft-versus-host disease.

Stephen Murphy1, Vu H Nguyen.   

Abstract

Our understanding of graft-versus-host disease (GVHD) has mostly focused on the role of adaptive immunity in mediating host-recipient genetic disparity in the proinflammatory milieu. These experimental models rarely address the unique biology of GVHD whereby it targets mainly epithelial compartments of the intestine, skin, and liver. Recent discoveries of the role of the microbiota in health and disease have reinvigorated questions about how the innate immunity contributes to the pathogenesis of GVHD and perhaps explains its tissue tropism. In this review, we discuss findings indicating the potential role of pattern-recognition receptors of the innate immune system in mediating GVHD and present evidence that shows how the microbiota interact with the host to shape health and disease. These findings support a reevaluation of our current clinical practice and encourage further studies of the potential critical role of the gut microbiota in hematopoietic stem cell transplant which may lead to novel preventive and therapeutic targets against GVHD.

Entities:  

Mesh:

Year:  2011        PMID: 21663498     DOI: 10.3109/10428194.2011.580476

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN: 1026-8022


  24 in total

Review 1.  Pattern recognition receptors in immune disorders affecting the skin.

Authors:  Heleen D de Koning; Anna Simon; Patrick L J M Zeeuwen; Joost Schalkwijk
Journal:  J Innate Immun       Date:  2012-03-06       Impact factor: 7.349

Review 2.  Prevention of graft-vs.-host disease.

Authors:  Andrew R Rezvani; Rainer F Storb
Journal:  Expert Opin Pharmacother       Date:  2012-07-07       Impact factor: 3.889

3.  Serum miR-29a Is Upregulated in Acute Graft-versus-Host Disease and Activates Dendritic Cells through TLR Binding.

Authors:  Parvathi Ranganathan; Apollinaire Ngankeu; Nina C Zitzer; PierPaolo Leoncini; Xueyan Yu; Lucia Casadei; Kishore Challagundla; Dawn K Reichenbach; Sabrina Garman; Amy S Ruppert; Stefano Volinia; Jessica Hofstetter; Yvonne A Efebera; Steven M Devine; Bruce R Blazar; Muller Fabbri; Ramiro Garzon
Journal:  J Immunol       Date:  2017-02-03       Impact factor: 5.422

4.  Bacterial foodborne infections after hematopoietic cell transplantation.

Authors:  Nicole M Boyle; Sara Podczervinski; Kim Jordan; Zach Stednick; Susan Butler-Wu; Kerry McMillen; Steven A Pergam
Journal:  Biol Blood Marrow Transplant       Date:  2014-07-12       Impact factor: 5.742

Review 5.  Intestinal microbiota-related effects on graft-versus-host disease.

Authors:  Yusuke Shono; Melissa D Docampo; Jonathan U Peled; Suelen M Perobelli; Robert R Jenq
Journal:  Int J Hematol       Date:  2015-03-27       Impact factor: 2.490

Review 6.  Clostridium difficile infection among hematopoietic stem cell transplant recipients: beyond colitis.

Authors:  Carolyn D Alonso; Kieren A Marr
Journal:  Curr Opin Infect Dis       Date:  2013-08       Impact factor: 4.915

Review 7.  The lung microbiome after lung transplantation.

Authors:  Julia Becker; Valeriy Poroyko; Sangeeta Bhorade
Journal:  Expert Rev Respir Med       Date:  2014-04       Impact factor: 3.772

Review 8.  Role of the intestinal mucosa in acute gastrointestinal GVHD.

Authors:  Jonathan U Peled; Alan M Hanash; Robert R Jenq
Journal:  Blood       Date:  2016-11-17       Impact factor: 22.113

9.  Recipient NK cell inactivation and intestinal barrier loss are required for MHC-matched graft-versus-host disease.

Authors:  Sam C Nalle; H Aimee Kwak; Karen L Edelblum; Nora E Joseph; Gurminder Singh; Galina F Khramtsova; Eric D Mortenson; Peter A Savage; Jerrold R Turner
Journal:  Sci Transl Med       Date:  2014-07-02       Impact factor: 17.956

10.  The HSP90 inhibitor, 17AAG, protects the intestinal stem cell niche and inhibits graft versus host disease development.

Authors:  A-L Joly; A Deepti; A Seignez; A Goloudina; S Hebrard; E Schmitt; S Richaud; E Fourmaux; A Hammann; A Collura; M Svrcek; G Jego; E Robinet; E Solary; O Demidov; E Kohli; C Garrido
Journal:  Oncogene       Date:  2015-09-14       Impact factor: 9.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.